Clinical characteristics and healthcare utilization of patients with multicentric Castleman disease

Corey Casper, Dana Y. Teltsch, Don Robinson, Marie Pierre Desrosiers, Philip Rotella, Angela Dispenzieri, Ming Qi, Thomas Matthew Habermann, Matthew W. Reynolds

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Multicentric Castleman disease (MCD) is a rare lymphoproliferative disease. Little is known about how patient clinical features and healthcare utilization varies by human immunodeficiency virus (HIV) status and disease subtype. Data of MCD patients identified between 2000 and 2009 were collected from medical records at two United States treatment centres. Clinical, demographic, and biochemical characteristics, drug therapies and medical utilization were descriptively reported by HIV status and cell histology, and statistically compared with the Fisher's Exact and Kruskal-Wallis tests. Patients (n = 59) had a pathologically and clinically confirmed MCD diagnosis: plasmacytic (42%), hyaline vascular (29%) and mixed (15%); 10% had HIV infection. In the first year after diagnosis, MCD patients on average saw a healthcare provider more than six times, were hospitalized at least once and underwent frequent radiological and laboratory testing. Rituximab was the most commonly used drug therapy, followed by corticosteroids and conventional chemotherapy. One- and 2-year survival was excellent in HIV-negative patients (100% and 97%, respectively) but inferior for HIV-positive cases (67% and 67%, respectively). Heterogeneous treatment decisions were observed in this MCD study; HIV status was the only distinguishing clinical criteria associated with pharmacotherapies. Additional research is necessary to guide treatment of this rare lymphoproliferative disorder.

Original languageEnglish (US)
Pages (from-to)82-93
Number of pages12
JournalBritish Journal of Haematology
Volume168
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

HIV
Delivery of Health Care
Drug Therapy
Virus Diseases
Hyalin
Lymphoproliferative Disorders
Rare Diseases
Health Personnel
Medical Records
Blood Vessels
Multi-centric Castleman's Disease
Histology
Adrenal Cortex Hormones
Therapeutics
Demography
Survival
Research

Keywords

  • Castleman disease
  • Healthcare utilization
  • Lymphoproliferative disorder
  • Treatment

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Casper, C., Teltsch, D. Y., Robinson, D., Desrosiers, M. P., Rotella, P., Dispenzieri, A., ... Reynolds, M. W. (2015). Clinical characteristics and healthcare utilization of patients with multicentric Castleman disease. British Journal of Haematology, 168(1), 82-93. https://doi.org/10.1111/bjh.13111

Clinical characteristics and healthcare utilization of patients with multicentric Castleman disease. / Casper, Corey; Teltsch, Dana Y.; Robinson, Don; Desrosiers, Marie Pierre; Rotella, Philip; Dispenzieri, Angela; Qi, Ming; Habermann, Thomas Matthew; Reynolds, Matthew W.

In: British Journal of Haematology, Vol. 168, No. 1, 01.01.2015, p. 82-93.

Research output: Contribution to journalArticle

Casper, Corey ; Teltsch, Dana Y. ; Robinson, Don ; Desrosiers, Marie Pierre ; Rotella, Philip ; Dispenzieri, Angela ; Qi, Ming ; Habermann, Thomas Matthew ; Reynolds, Matthew W. / Clinical characteristics and healthcare utilization of patients with multicentric Castleman disease. In: British Journal of Haematology. 2015 ; Vol. 168, No. 1. pp. 82-93.
@article{1c3060d17bfd4bc197c0e794b2cbc0c7,
title = "Clinical characteristics and healthcare utilization of patients with multicentric Castleman disease",
abstract = "Multicentric Castleman disease (MCD) is a rare lymphoproliferative disease. Little is known about how patient clinical features and healthcare utilization varies by human immunodeficiency virus (HIV) status and disease subtype. Data of MCD patients identified between 2000 and 2009 were collected from medical records at two United States treatment centres. Clinical, demographic, and biochemical characteristics, drug therapies and medical utilization were descriptively reported by HIV status and cell histology, and statistically compared with the Fisher's Exact and Kruskal-Wallis tests. Patients (n = 59) had a pathologically and clinically confirmed MCD diagnosis: plasmacytic (42{\%}), hyaline vascular (29{\%}) and mixed (15{\%}); 10{\%} had HIV infection. In the first year after diagnosis, MCD patients on average saw a healthcare provider more than six times, were hospitalized at least once and underwent frequent radiological and laboratory testing. Rituximab was the most commonly used drug therapy, followed by corticosteroids and conventional chemotherapy. One- and 2-year survival was excellent in HIV-negative patients (100{\%} and 97{\%}, respectively) but inferior for HIV-positive cases (67{\%} and 67{\%}, respectively). Heterogeneous treatment decisions were observed in this MCD study; HIV status was the only distinguishing clinical criteria associated with pharmacotherapies. Additional research is necessary to guide treatment of this rare lymphoproliferative disorder.",
keywords = "Castleman disease, Healthcare utilization, Lymphoproliferative disorder, Treatment",
author = "Corey Casper and Teltsch, {Dana Y.} and Don Robinson and Desrosiers, {Marie Pierre} and Philip Rotella and Angela Dispenzieri and Ming Qi and Habermann, {Thomas Matthew} and Reynolds, {Matthew W.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1111/bjh.13111",
language = "English (US)",
volume = "168",
pages = "82--93",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Clinical characteristics and healthcare utilization of patients with multicentric Castleman disease

AU - Casper, Corey

AU - Teltsch, Dana Y.

AU - Robinson, Don

AU - Desrosiers, Marie Pierre

AU - Rotella, Philip

AU - Dispenzieri, Angela

AU - Qi, Ming

AU - Habermann, Thomas Matthew

AU - Reynolds, Matthew W.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Multicentric Castleman disease (MCD) is a rare lymphoproliferative disease. Little is known about how patient clinical features and healthcare utilization varies by human immunodeficiency virus (HIV) status and disease subtype. Data of MCD patients identified between 2000 and 2009 were collected from medical records at two United States treatment centres. Clinical, demographic, and biochemical characteristics, drug therapies and medical utilization were descriptively reported by HIV status and cell histology, and statistically compared with the Fisher's Exact and Kruskal-Wallis tests. Patients (n = 59) had a pathologically and clinically confirmed MCD diagnosis: plasmacytic (42%), hyaline vascular (29%) and mixed (15%); 10% had HIV infection. In the first year after diagnosis, MCD patients on average saw a healthcare provider more than six times, were hospitalized at least once and underwent frequent radiological and laboratory testing. Rituximab was the most commonly used drug therapy, followed by corticosteroids and conventional chemotherapy. One- and 2-year survival was excellent in HIV-negative patients (100% and 97%, respectively) but inferior for HIV-positive cases (67% and 67%, respectively). Heterogeneous treatment decisions were observed in this MCD study; HIV status was the only distinguishing clinical criteria associated with pharmacotherapies. Additional research is necessary to guide treatment of this rare lymphoproliferative disorder.

AB - Multicentric Castleman disease (MCD) is a rare lymphoproliferative disease. Little is known about how patient clinical features and healthcare utilization varies by human immunodeficiency virus (HIV) status and disease subtype. Data of MCD patients identified between 2000 and 2009 were collected from medical records at two United States treatment centres. Clinical, demographic, and biochemical characteristics, drug therapies and medical utilization were descriptively reported by HIV status and cell histology, and statistically compared with the Fisher's Exact and Kruskal-Wallis tests. Patients (n = 59) had a pathologically and clinically confirmed MCD diagnosis: plasmacytic (42%), hyaline vascular (29%) and mixed (15%); 10% had HIV infection. In the first year after diagnosis, MCD patients on average saw a healthcare provider more than six times, were hospitalized at least once and underwent frequent radiological and laboratory testing. Rituximab was the most commonly used drug therapy, followed by corticosteroids and conventional chemotherapy. One- and 2-year survival was excellent in HIV-negative patients (100% and 97%, respectively) but inferior for HIV-positive cases (67% and 67%, respectively). Heterogeneous treatment decisions were observed in this MCD study; HIV status was the only distinguishing clinical criteria associated with pharmacotherapies. Additional research is necessary to guide treatment of this rare lymphoproliferative disorder.

KW - Castleman disease

KW - Healthcare utilization

KW - Lymphoproliferative disorder

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84915747258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84915747258&partnerID=8YFLogxK

U2 - 10.1111/bjh.13111

DO - 10.1111/bjh.13111

M3 - Article

C2 - 25208471

AN - SCOPUS:84915747258

VL - 168

SP - 82

EP - 93

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -